June 23, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will host a webinar titled “R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis” today, June 23, 2026, at 2:00pm ET. argenx management and scientific leadership will be joined by external key opinion leaders:Avery LaChance, MD, MPH, FAAD, Associate Professor of Dermatology, Harvard Medical School; Director of Connective Tissue Disease Clinic Arjun Seth, MD, Assistant Professor, Neurology (Neuromuscular Disease), Northwestern University Feinberg School of Medicine Rohit Aggarwal, MD, MS, Professor of Medicine, University of Pittsburgh, and Co-Director of UPMC Myositis CenterWebcast Information A live webcast...

Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapsesCenrifki represents a significant advancement for people living with SPMS by targeting disability progression Approval based on the HERCULES phase 3 study in nrSPMS with supporting data from the GEMINI 1 and 2 phase 3 studies in RMSParis, June 23, 2026. The European Commission has approved Cenrifki (tolebrutinib) for the treatment of secondary progressive multiple sclerosis (SPMS) without relapses in the last two years. This follows the positive opinion by the European Medicines Agency’s Committee for Medicinal Products for Human Use. The approval is based on results from the HERCULES phase 3 study (clinical study identifier: NCT04411641) in non-relapsing SPMS (nrSPMS), with...

Sanofi’s Wayrilz approved in Japan to treat immune thrombocytopeniaWayrilz is a BTK inhibitor that works through multi-immune modulation to help address the underlying causes of immune thrombocytopenia (ITP) Approval based on the LUNA 3 phase 3 study that demonstrated rapid and durable platelet response and improvements in other symptoms ITP is a rare disease of complex immune dysregulation leading to lower platelet counts, bleeding, and reduced quality of lifeParis, June 23, 2026. The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization to Wayrilz (rilzabrutinib), a novel oral reversible Bruton’s tyrosine kinase inhibitor (BTKi), for the treatment of persistent or chronic immune thrombocytopenia (ITP) in patients who do not respond sufficiently to other treatments or in whom tolerability...

The shares in SalMar ASA will be quoted ex-dividend of NOK 10.00 per share as from today, 23 June 2026. This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Opportunistic capital raise with proceeds used to enhance strategic flexibility to invest for future growth Approximately $290 million of the proceeds to be used to repurchase shares concurrently with the Offering Additionally, a portion of the proceeds to be used to purchase capped calls intended to offset any share dilution until a 125% premium to the last reported sale price of Robinhood’s Class A common stock on the date of pricing MENLO PARK, Calif., June 22, 2026 (GLOBE NEWSWIRE) — Robinhood Markets, Inc. (“Robinhood”) (NASDAQ: HOOD) today announced that it has priced an offering of $2.0 billion in aggregate principal amount of 0.00% convertible senior notes due 2029 (the “Notes”) in a private placement (the “Offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A of the Securities...

SAN MATEO, Calif., June 22, 2026 (GLOBE NEWSWIRE) — Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in 1×1 investor meetings at the Leerink Partners Therapeutics Forum in Boston, MA on July 15, 2026. Inducement Grant In connection with the hiring of two employees, the Compensation Committee of Sagimet’s Board of Directors approved that an inducement grant of 34,300 stock options, in aggregate to purchase shares of the Company’s Series A common stock, be granted on June 22, 2026 to the newly hired employees. The option awards were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual’s employment compensation...

MONTREAL, June 22, 2026 (GLOBE NEWSWIRE) — Stingray Group Inc. (TSX: RAY) (“Stingray” or the “Corporation”) wishes to advise that there will be a delay in the filing of its audited consolidated financial statements for the year ended March 31, 2026, management’s discussion and analysis thereof and the CEO and CFO certificates associated therewith (collectively, the “Required Disclosure”), which are due to be filed on or before June 29, 2026 (the “Filing Deadline”) pursuant to applicable securities laws. This delay is due to the fact that Stingray’s auditor has not completed the required work to conclude the audit. Stingray understands that the unanticipated delay in completing the audit of its consolidated financial statements for the year ended March 31, 2026 is in large part due to the complexity of integrating the acquisitions...

TORONTO, ONTARIO, June 22, 2026 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) announced the next steps in connection with changes to the Company’s share capital (the “Share Capital Amendment”). The Share Capital Amendment was approved at the Company’s annual general and special meeting of shareholders held on June 17, 2026. The Share Capital Amendment consists of (i) a consolidation (the “Consolidation”) of the Company’s common shares (“Common Shares”) on the basis of one post-Consolidation Common Share for every 150 pre-Consolidation Common Shares; and (ii) an immediate subsequent split (the “Split”) of the Common Shares on the basis of 50 Common Shares for every one post-Consolidation Common Share. The Share Capital Amendment is expected to become effective on July 3, 2026...

CALGARY, Alberta, June 22, 2026 (GLOBE NEWSWIRE) — Questor Technology Inc. (“Questor” or the “Company”) (TSX-V: QST) announces that its Annual General Meeting of Shareholders (the “Meeting”) has been rescheduled to and will be held on Wednesday, September 9, 2026 at 1:00 p.m. MDT at the office of Norton Rose Fulbright Canada LLP in Calgary, Alberta. The Meeting was originally scheduled for June 15, 2026, but was postponed due to, among other reasons, an inadvertent third-party delay in mailing meeting materials. The purposes of the Meeting are: (1) receiving the audited consolidated financial statements of the Company for the year ended December 31, 2025 and the auditors’ report thereon; (2) fixing the number of directors to be elected at the Meeting by ordinary resolution; (3) electing the directors for the ensuing year by ordinary...

VANCOUVER, British Columbia, June 22, 2026 (GLOBE NEWSWIRE) — Teck Resources Limited (TSX: TECK.A and TECK.B, NYSE: TECK) (“Teck”) today announced the appointment of Edwin Shadeo as Acting Vice President, Investor Relations and Treasurer, effective immediately. Mr. Shadeo succeeds Emma Chapman, who is leaving Teck to pursue new professional opportunities. “As Treasurer, Edwin has developed extensive relationships within the capital markets community, building on his deep understanding of our business. This, combined with his long-standing experience in investor relations, equips him well to lead our engagement with shareholders,” said President and CEO Jonathan Price. “I would also like to thank Emma for her leadership and outstanding contributions to Teck during her time as Vice President, Investor Relations.” Mr. Shadeo joined...